Artemisia annua

Sensational artemisinin-piperaquine for treatment of COVID-19 in prospect

Retrieved on: 
Wednesday, November 3, 2021
People, Coronavirus, Research, Artemisinin, National Medical Products Administration, Guangzhou University, Guangzhou Medical University, Disease, Association, Tablet, Firestone Institute for Respiratory Health, Guangzhou University of Chinese Medicine, Infection, Joint Medical Service (Germany), TCM, Efficacy, National Health Commission, Genetics, Malaria, Hospital, Social media, International Journal of Antimicrobial Agents, COVID-19, Safety, Antimicrobial, Xinhui People's Hospital, Observation, Artemisia annua, Treatment, Canadian International Council, Pharmaceutical industry

These drugs first came to the industry's attention after the International Journal of Antimicrobial Agents published a paper titled "Safety and Efficacy of Artemisinin-Piperaquine for Treatment of COVID-19".

Key Points: 
  • These drugs first came to the industry's attention after the International Journal of Antimicrobial Agents published a paper titled "Safety and Efficacy of Artemisinin-Piperaquine for Treatment of COVID-19".
  • This implies how the scientific community and the general public are in desperate need of effective drug treatments for COVID-19.
  • And they have been the drug of first choice recommended by the National Health Commission of China since 2009.
  • Going ahead, the drug is expected to have a greater role to play in the treatment of other diseases," said Zhu Layi, president of Guangdong New South Group.

Mateon Therapeutics to fund observational studies of Artemisinin in developing countries

Retrieved on: 
Monday, July 13, 2020
Articles, Medicine, Oxygen compounds, Organic peroxides, Artemisinin, Commercialization of traditional medicines, Traditional Chinese medicine, Artemisia annua, Artemisia, Wormwood, Herbal medicine, Pandemic

AGOURA HILLS, Calif., July 13, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics (OTCQB: MATN), a leading developer of TGF- therapeutics, announced today that it will fund observational studies for Artemisinin, an herbal supplement, that demonstrated potent in vitro activity against SARS-CoV-2, the COVID-19 virus.

Key Points: 
  • AGOURA HILLS, Calif., July 13, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics (OTCQB: MATN), a leading developer of TGF- therapeutics, announced today that it will fund observational studies for Artemisinin, an herbal supplement, that demonstrated potent in vitro activity against SARS-CoV-2, the COVID-19 virus.
  • By collecting data from multiple clinical observational studies globally, the company expects to establish Artemisinin efficacy against COVID-19 as an affordable front-line treatment for this pandemic in low resources countries.
  • The company is inviting nonprofits such as non-government organizations to participate in this trial if they have the logistics to participate in observational trials and to distribute the Artemisinin in their home countries.
  • Artemisinin is derived from an abundantly grown herb Artemisia annua L. (Sweet wormwood) and has been used medicinally to treat fevers for centuries in eastern countries.

Mateon Expands its COVID-19 Therapeutic Program to include Artemisinin

Retrieved on: 
Wednesday, April 8, 2020
Infectious diseases, Organic compounds, Oxygen compounds, Organic peroxides, Artemisinin, Commercialization of traditional medicines, Traditional Chinese medicine, Artemisia annua, RTT, Artemisia, Malaria, Artesunate suppositories

Artemisinin is a natural derivative from the Asian herb Artemisia annua and has been used to treat malaria.

Key Points: 
  • Artemisinin is a natural derivative from the Asian herb Artemisia annua and has been used to treat malaria.
  • Artemisinin derived from Chinese herb Artemisia annua L. (Sweet wormwood) has been used medicinally to treat fevers for centuries in China.
  • Dr. Vuong Trieu, President and Chief Executive Officer of Mateon stated: The discovery of Artemisinin through our fruitful collaboration with Golden Mountain Partners could be the solution for COVID-19 pandemic.
  • Like other potential COVID-19 therapeutic agents such as Hydrochloroquine and Remesidivir, the efficacy of Artemisinin remained to be tested in well controlled and sufficiently powered clinical trials but Artemisinin has many advantages against COVID-19.